Synthesis of (3-Amino-7-chloro-8-methyl-1,1-dioxo-4H-1,5,2-benzo[f]dithiazepin-4-ylidene)acetic Acid De rivatives as Potential Antitumor Agents

• Autorzy: Brzozowski Z. , Sączewski F. , Sławiński J.
• Języki publikacji: EN

Abstrakty

EN

Several 3-amino-7-chloro-8-methyl-1,1-dioxo-4H-1,5,2- benzo[f]dithiazepin- 4-yli - dene)acetic acid derivatives (2, 4-15) have been syn the sized. The in vi tro antitumor activity of the compounds 8, 10-12 and 14-15 have been evaluated in the US National Cancer Institute. Screening data indicated that compounds 10, 11 and 14 exhibited high activity against 1-28 human tumor cell lines (GI50 < 0.01 to 3.0 mM). [3-(Benzo-2,1,3-thiadiazol-4-ylamino)-7-chloro-8-methyl-1,1-dioxo-4H-1,5,2-benzo[f]dithiazepin-4--ylidene]acetic acid 11 is the prominent one due to remark able activity and selectivity toward CNS cancer SF-295 cell line of (GI50 < 0.01 mM; TGI = 0.05 mM) and BT-549 cell line of breast cancer (GI50 < 0.01 mM; TGI = 0.09 mM).

Słowa kluczowe

EN

(1,1-dioxo-4H-1,5,2-benzo[f]dithiazepines; sulfonamides; antitumor activity

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2007
• Tom: Vol. 81, nr 12
• Strony: 2133--2142
• Opis fizyczny: Bibliogr. 30 poz., rys.

Twórcy

autor

Brzozowski Z.

autor

Sączewski F.

autor

Sławiński J.

• Department of Chemical Technology of Drugs, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland,

Bibliografia

• 1. Casini A., Scozzafava A., Mastrolorenzo A. and Supuran C.T., Curr. Cancer Drug Targets, 2,55 (2002).
• 2. Scozzafava A., Casini A. and Supuran C.T., Curr. Med Chem., 9, 1167 (2002).
• 3. Supuran C.T., Casini A. and Scozzafava A., Med Res. Rev., 23, 535 (2003).
• 4. Scozzafava A., Owa T., Mastrolorenzo A. and Supuran C.T., Curr. Med Chem., 10, 925 (2003).
• 5. Brzozowski Z., Acta Polon. Pharm. Drug Res., 52, 91 (1995).
• 6. Brzozowski Z., Acta Polon. Pharm. Drug Res., 52, 287 (1995).
• 7. Brzozowski Z., Acta Polon. Pharm. Drug Res., 53, 269 (1996).
• 8. Brzozowski Z., Acta Polon. Pharm. Drug Res., 55, 375 (1998).
• 9. Brzozowski Z. and Kórnicka A., Acta Polon. Pharm. Drug Res., 56, 135 (1999).
• 10. Brzozowski Z., Sączewski F. and Gdaniec M., Eur. J. Med Chem., 37, 285 (2002).
• 11. Sławiński J. and Gdaniec M., Eur. J. Med Chem., 40, 377 (2005).
• 12. Sławiński J. and Brzozowski Z., Eur. J. Med Chem., 41, 1180 (2006).
• 13. Neamati N., Mazumder A., Sunder S., Owen J.H., Schultz R.J. and Pommier Y., Antiviral Chem. Chemother.,8,485(1997).
• 14. Brzozowski Z., Acta Polon. Pharm. Drug Res., 55, 473 (1998).
• 15. Kuo Ch.L., Assefa H., Brzozowski Z., Sławiński J., Sączewski F., Buolamwini J.K. and Neamati N., J. Med Chem., 47, 385 (2004).
• 16. Brzozowski Z., Sączewski F. and Gdaniec M., Bioorg. Med Chem., 11, 3673 (2003).
• 17. Brzozowski Z., Sączewski F. and Gdaniec M., Eur J. Med Chem., 38, 991 (2003).
• 18. Brzozowski Z., Acta Polon. Pharm. Drug Res., 54, 293 (1997).
• 19. Brzozowski Z. and Sączewski F., J. Med. Chem., 45, 430 (2002).
• 20. Brzozowski Z., Sączewski F. and Neamati N., Bioorg. Med Chem., 14, 2985 (2006).
• 21. Pomarnacka E., Kórnicka A. and Sączewski F., Heterocycles, 55, 753 (2001).
• 22. Brzozowski Z., Sączewski F., Sanchez T., Kuo Ch.L., Gdaniec M. and Neamati N., Bioorg. Med. Chem., 12, 3663 (2004).
• 23. Brzozowski Z., Sączewski F. and Neamati N., Bioorg. Med Chem. Lett., 16, 5298 (2006).
• 24. Brzozowski Z. and Sławiński J., Acta Polon. Pharm., 41, 133 (1984).
• 25. Krubsack A.J. and Higa T., Tetrahedron Lett., 49, 5149 (l968).
• 26. Cushman M. and Cheng L., J. Org. Chem., 43, 3781 (1978).
• 27. The geometry of 4 was fully optimized using a semiempirical AM1 method. The calculations were carried out using the Spartan Pro program version 1,0,5 (2000), distributed by Waverunction Inc.
• 28. Boyd M.R., Am. Assoc. Cancer Res., 30, 652 (1989).
• 29. Monks A.P., Scudiero D.A., Skehan R, Shoemaker R., Poull K.D., Vistica D., Hose C., Langley J.,Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Cambell H., Mayo J. and Boyd M.J., J. Natl. Cancer Inst., 83, 757 (1991).
• 30. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornance A.J.Jr., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Andersen N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausiville E.A., Zaharevitz D. W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E. and Paull K.D., Science, 275, 343 (1991).